Cure8 research brief
Berries are a familiar, dietary source of anti-inflammatory bioactive compounds that might help reduce intestinal inflammation and improve biomarkers relevant to IBD. Patients often seek safe, complementary strategies alongside medical therapy, so understanding the current evidence helps set realistic expectations.
Adults with IBD (especially people with ulcerative colitis), clinicians managing IBD, researchers designing dietary or phytochemical trials, and patients exploring complementary dietary approaches.
This review included 19 studies (16 animal studies and 3 clinical studies corresponding to 5 reports) through July 2026. Preclinical findings reported reduced pro-inflammatory cytokines, improved epithelial barrier integrity, and shifts in gut microbiota after berry interventions.
The limited clinical evidence (68 unique participants across the trials) reported some improvements in disease activity scores, fecal calprotectin, quality of life, and remission in ulcerative colitis, but the trials were small and heterogeneous.
The authors conclude the clinical data are preliminary and call for larger, rigorous randomized controlled trials to determine whether animal-model effects translate into meaningful benefits for people with IBD.
The article is a systematic review (abstract-level content provided). Most included studies were preclinical; only three small clinical trials with 68 participants inform human effects. Results are preliminary and heterogeneous, so larger randomized trials are needed.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: Ministero dell’università e della ricerca, award 202273HF83; award 202273HF83; Unione Europea, award P2022FAS5R; Ministero della Salute, award GR-2021-12375174; Ministero della Salute, award SG-2021–12375551; award GR-2021-12375174; award SG-2021–12375551
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This trial examines whether a blueberry-rich supplement can change inflammation, the microbiome, and intestinal barrier function in people with chronic colitis — topics many with IBD care about because diet and the...
The study suggests vitamin D might help the immune system tolerate gut bacteria better and lower intestinal inflammation, which could mean fewer symptoms or flares for people with Crohn’s disease or ulcerative colitis.
Non-invasive fecal lipid markers could help differentiate UC from CD and improve diagnostic molecular profiling in IBD if validated, which may be useful for patients and clinicians seeking less-invasive diagnostic tools.
